Koki A - Search Results

1

Effective diminution of amniotic prostaglandin production by selective inhibitors of cyclooxygenase type 2.

Sadovsky Y, Nelson DM, Muglia LJ, Gross GA, Harris KC, Koki A, Masferrer JL, Olson LM. Sadovsky Y, et al. Among authors: koki a. Am J Obstet Gynecol. 2000 Feb;182(2):370-6. doi: 10.1016/s0002-9378(00)70226-2. Am J Obstet Gynecol. 2000. PMID: 10694339

2

Cyclooxygenase-2 in human pathological disease.

Koki A, Khan NK, Woerner BM, Dannenberg AJ, Olson L, Seibert K, Edwards D, Hardy M, Isakson P, Masferrer JL. Koki A, et al. Adv Exp Med Biol. 2002;507:177-84. doi: 10.1007/978-1-4615-0193-0_28. Adv Exp Med Biol. 2002. PMID: 12664583 Review.

3

COX-2 inhibitors. A new class of antiangiogenic agents.

Masferrer JL, Koki A, Seibert K. Masferrer JL, et al. Among authors: koki a. Ann N Y Acad Sci. 1999;889:84-6. doi: 10.1111/j.1749-6632.1999.tb08726.x. Ann N Y Acad Sci. 1999. PMID: 10668485 Review.

4

Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.

Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Masferrer JL, et al. Among authors: koki at. Cancer Res. 2000 Mar 1;60(5):1306-11. Cancer Res. 2000. PMID: 10728691

5

Role of cyclooxygenases in angiogenesis.

Leahy KM, Koki AT, Masferrer JL. Leahy KM, et al. Among authors: koki at. Curr Med Chem. 2000 Nov;7(11):1163-70. doi: 10.2174/0929867003374336. Curr Med Chem. 2000. PMID: 11032965 Review.

6

Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers.

Koki AT, Khan NK, Woerner BM, Seibert K, Harmon JL, Dannenberg AJ, Soslow RA, Masferrer JL. Koki AT, et al. Prostaglandins Leukot Essent Fatty Acids. 2002 Jan;66(1):13-8. doi: 10.1054/plef.2001.0335. Prostaglandins Leukot Essent Fatty Acids. 2002. PMID: 12051953 Review.

7

Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.

Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Leahy KM, et al. Cancer Res. 2002 Feb 1;62(3):625-31. Cancer Res. 2002. PMID: 11830509

8

Celecoxib: a specific COX-2 inhibitor with anticancer properties.

Koki AT, Masferrer JL. Koki AT, et al. Cancer Control. 2002 Mar-Apr;9(2 Suppl):28-35. doi: 10.1177/107327480200902S04. Cancer Control. 2002. PMID: 11965228 Free article. Review.

9

Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites.

López-Parra M, Clària J, Planagumà A, Titos E, Masferrer JL, Woerner BM, Koki AT, Jiménez W, Altuna R, Arroyo V, Rivera F, Rodés J. López-Parra M, et al. Among authors: koki at. Br J Pharmacol. 2002 Feb;135(4):891-900. doi: 10.1038/sj.bjp.0704528. Br J Pharmacol. 2002. PMID: 11861316 Free PMC article.

10

Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder.

Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, Woerner BM, Snyder PW, Koki AT. Mohammed SI, et al. Among authors: koki at. Cancer Res. 1999 Nov 15;59(22):5647-50. Cancer Res. 1999. PMID: 10582676

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

40 results

Search Page